Conditions: Cystic Fibrosis
Intervention Type: Drug
Intervention Name: Tobramycin
Clinical Trials
The following are clinical trials from the Healia Clinical Trials Information Database that are researching the effect of the "Drug" intervention "Tobramycin" on "Cystic Fibrosis".
-
Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis Subjects
NCTID: NCT00420836
-
A Phase 1, Single-Dose, Open-Label, Two-Way Crossover, Pharmacoscintigraphy Study of Aerosol Delivery Characteristics (Measured by In Vivo Lung Deposition, Nebulization Time, Serum Tobramycin Concentrations, and Pharmacokinetic Parameters) and Safety of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (No Compressor) vs. PARI LC PLUS (TM) Jet Nebulizer (With Compressor) in Healthy Subjects and in Subjects With Cystic Fibrosis
NCTID: NCT00399945
-
Pharmacokinetic Bioequivalence Study of Nebcinal�� 150mg/3ml Administered by Aeroneb�� Idehaler�� Versus Tobi�� 300mg/5ml Administered by Pari LC Plus�� /Pulmoaide�� in Patients With Cystic Fibrosis.
NCTID: NCT01337219